Passage Deferred Long Term Liab from 2010 to 2024
| PASG Stock | USD 0.62 0.11 21.57% |
Deferred Long Term Liabilities | First Reported 2010-12-31 | Previous Quarter 180 K | Current Value 171 K | Quarterly Volatility 736.7 K |
Check Passage Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Passage Bio's main balance sheet or income statement drivers, such as Net Interest Income of 2.7 M, Interest Income of 2.7 M or Depreciation And Amortization of 2.8 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.52. Passage financial statements analysis is a perfect complement when working with Passage Bio Valuation or Volatility modules.
Passage | Deferred Long Term Liab |
Latest Passage Bio's Deferred Long Term Liab Growth Pattern
Below is the plot of the Deferred Long Term Liab of Passage Bio over the last few years. It is liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue. Passage Bio's Deferred Long Term Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Passage Bio's overall financial position and show how it may be relating to other accounts over time.
| Deferred Long Term Liab | 10 Years Trend |
|
Deferred Long Term Liab |
| Timeline |
Passage Deferred Long Term Liab Regression Statistics
| Arithmetic Mean | 1,196,733 | |
| Geometric Mean | 818,571 | |
| Coefficient Of Variation | 61.56 | |
| Mean Deviation | 671,022 | |
| Median | 1,700,000 | |
| Standard Deviation | 736,744 | |
| Sample Variance | 542.8B | |
| Range | 1.5M | |
| R-Value | (0.82) | |
| Mean Square Error | 191.5B | |
| R-Squared | 0.67 | |
| Significance | 0.0002 | |
| Slope | (135,082) | |
| Total Sum of Squares | 7.6T |
Passage Deferred Long Term Liab History
About Passage Bio Financial Statements
Passage Bio stakeholders use historical fundamental indicators, such as Passage Bio's Deferred Long Term Liab, to determine how well the company is positioned to perform in the future. Although Passage Bio investors may analyze each financial statement separately, they are all interrelated. For example, changes in Passage Bio's assets and liabilities are reflected in the revenues and expenses on Passage Bio's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Passage Bio. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Deferred Long Term Liabilities | 180 K | 171 K |
Currently Active Assets on Macroaxis
When determining whether Passage Bio is a strong investment it is important to analyze Passage Bio's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Passage Bio's future performance. For an informed investment choice regarding Passage Stock, refer to the following important reports:Check out the analysis of Passage Bio Correlation against competitors. For more detail on how to invest in Passage Stock please use our How to Invest in Passage Bio guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Passage Bio. If investors know Passage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Passage Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.17) | Return On Assets (0.34) | Return On Equity (0.64) |
The market value of Passage Bio is measured differently than its book value, which is the value of Passage that is recorded on the company's balance sheet. Investors also form their own opinion of Passage Bio's value that differs from its market value or its book value, called intrinsic value, which is Passage Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Passage Bio's market value can be influenced by many factors that don't directly affect Passage Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Passage Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Passage Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Passage Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.